Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
Pietro Quaglino(Department of Medical Sciences), Maria Grazia Bernengo(University of Milan), Paola Savoia(University of Turin), N Cappello(University of Milan), B Salomone, Simona Osella‐Abate, Federica Marenco, Michela Ortoncelli, Maria Teresa Fierro(University of Turin)
Cited by 186
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas
|Journal of the American Academy of Dermatology|2002|493
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452